ArticleJournal of neurology2026
Muscle biopsy in genomic era: real-world diagnostic and clinical implications over 10 years.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnostic role of muscle biopsy has evolved with the increasing availability of next-generation sequencing (NGS). However, real-world data on its clinical impact in contemporary neuromuscular practice remain limited.
objectiveTo evaluate the diagnostic yield of muscle biopsy in a 10 year consecutive cohort, assessing concordance across clinical suspicion, histopathological findings, and final clinical diagnosis, and exploring demographic predictors of biopsy outcome.
methodsA retrospective cohort study of all consecutive muscle biopsies performed at a single tertiary neuromuscular center (2015-2025). Concordance analysis was performed at two levels: clinical suspicion vs. biopsy conclusion, and biopsy conclusion vs. final diagnosis at the last follow-up. Sex- and age-related differences across biopsy categories were evaluated using chi-square and Kruskal-Wallis tests.
resultsAmong 401 consecutive biopsies (56.9% male; median age 49 years), overall concordance between clinical suspicion and biopsy conclusion was 42.3%. Concordance with final clinical diagnosis was substantially higher, reaching 94.0% for idiopathic inflammatory myopathies (IIMs) among evaluable cases. Non-specific myopathic findings and normal biopsies accounted for 36.0% of cases; however, patients with non-specific myopathic findings were significantly more likely to receive a conclusive diagnosis at follow-up than those with normal biopsies (43.8% vs. 23.4%; OR 2.54, 95% CI 1.23-5.26, p = 0.011). Sex distribution differed significantly across biopsy categories (p < 0.001), with IIMs showing marked female predominance (69.1%).
conclusionsMuscle biopsy retains high diagnostic value in contemporary neuromuscular practice when applied to clinically selected patients. Beyond establishing specific diagnoses, biopsy findings carry prognostic significance and provide demographic signatures that reinforce their clinical validity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.